Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 33

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Paroxysmal nocturnal haemoglobinuria16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Myocardial infarction

Not yet recruiting

Ticagrelor monotherapy vs ticagrelor plus acetylsalicylic acid in patients with myocardial infarction treated medically

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Montreal Heart Institute

Cerebrovascular accident

Not yet recruiting

Rimonabant for Improving Walking Ability in Post‑Stroke Patients in the Chronic Phase

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Cerebrovascular accident

Not yet recruiting

Effect of Rimonabant on Functional Recovery in Subacute Stroke Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Coronary artery disease+2

Not yet recruiting

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic coronary syndrome

Not yet recruiting

Short Dual Antiplatelet Therapy with Ticagrelor, Aspirin and Clopidogrel vs Standard Therapy in Chronic Coronary Syndrome Patients Undergoing PCI

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Azienda Ospedaliera Universitaria Gaetano Martino Messina

Embolism venous

Not yet recruiting

Apixaban for Preventing Blood Clots in Adults Receiving Neoadjuvant Therapy for Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-Yhtymae

VEXAS syndrome

Not yet recruiting

Randomized Study of SIR9900 for Safety and Effectiveness in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Coronary artery disease+1

Not yet recruiting

Oral versus intravenous tranexamic acid to reduce bleeding in patients undergoing off‑pump coronary artery bypass surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid

Migraine without aura

Not yet recruiting

Study of apremilast‑induced headache and migraine in women with migraine without aura

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Apremilast
  • Sponsor:Syddansk Universitet (University of Southern Denmark)

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.